| Literature DB >> 32107559 |
Lukas Ronner1, Nikolai Podoltsev2, Jason Gotlib3, Mark L Heaney4, Andrew T Kuykendall5, Casey O'Connell6, Jamile Shammo7, Angela G Fleischman8, Robyn M Scherber9, Ruben Mesa9, Abdulraheem Yacoub10, Cecelia Perkins3, Shelby Meckstroth11, Lindsey Behlman2, Matthew Chiaramonte4, Mahta Salehi6, Kimia Ziadkhanpour1, Hellen Nguyen8, Olivia Siwoski10, Annie Kwok Hung9, Michelle Janania Martinez9, Jenny Nguyen8, Sagar Patel6, Revathi Kollipara7, Ami Dave7, Megan Randall7, Michael Grant7, Mitchell Harrison7, Paola Fernandez Soto7, Douglas Tremblay12, Ronald Hoffman12, Erin Moshier13, John Mascarenhas12.
Abstract
There are unresolved questions regarding the association between persistent leukocytosis and risk of thrombosis and disease evolution in polycythemia vera (PV), as much of the published literature on the topic does not appropriately use repeated-measures data or time-dependent modeling to answer these questions. To address this knowledge gap, we analyzed a retrospective database of 520 PV patients seen at 10 academic institutions across the United States. Taking hematologic laboratory data at ∼3-month intervals (or as available) for all patients for duration of follow-up, we used group-based trajectory modeling to identify latent clusters of patients who follow distinct trajectories with regard to their leukocyte, hematocrit, and platelet counts over time. We then tested the association between trajectory membership and hazard of 2 major outcomes: thrombosis and disease evolution to myelofibrosis, myelodysplastic syndrome, or acute myeloid leukemia. Controlling for relevant covariates, we found that persistently elevated leukocyte trajectories were not associated with the hazard of a thrombotic event (P = .4163), but were significantly associated with increased hazard of disease evolution in an ascending stepwise manner (overall P = .0002). In addition, we found that neither hematocrit nor platelet count was significantly associated with the hazard of thrombosis or disease evolution.Entities:
Mesh:
Year: 2020 PMID: 32107559 PMCID: PMC7205813 DOI: 10.1182/blood.2019003347
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113